‘Emily’ is a Levenorgestrel releasing intra uterine system (LNG-IUS) which releases 20 mcg of LNG per day for a period of 5 years. The use of LNG-IUS for contraception and for the treatment of AUB was relatively low owing to its poor availability and high cost (cost of innovator product is Rs.8205/- until 2013) & lack of insurance coverage. To address this unmet need of a cost-effective LNG IUS, HLL introduced Emily. The cost of an Emily LNG IUS is Rs. 2664/- (USD 41) only.
Emily is effectively used to treat Abnormal Uterine Bleeding (AUB). Emily has the potential to treat a range of pre-existing gynaecological conditions such as heavy menstrual bleeding due to a wide range of underlying causes, endometrial hyperplasia, uterine fibroids, adenomyosis, and endometriosis. In line with the performance of the innovator product. The phase IV clinical study with Emily has shown 93% efficacy in reducing menstrual bleeding, and also improving the quality of life of women. [International Journal of Gynecology and Obstetrics 129(2015) 114-117]. Introduction of Emily resulted in reduction in cost of the innovator product by 50% in India, still Emily is currently 50% cheaper than the innovator product.
Website : www.emily.org.in